Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1

Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1

An important factor associated with primary resistance to immune-checkpoint therapies (ICT) is a “cold” tumor microenvironment (TME), characterized by the absence of T cell infiltration and a non-inflammatory milieu. Whole-exome and RNA sequencing to predict neoantigen expression was performed on th...

Full description

Bibliographic Details
Main Authors: Changbo Sun, Koji Nagaoka, Yukari Kobayashi, Hidewaki Nakagawa, Kazuhiro Kakimi, Jun Nakajima
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Cancers
Subjects:
neoantigen
DC vaccine
immunotherapy
checkpoint
combination therapy
tumor microenvironment
Online Access:https://www.mdpi.com/2072-6694/13/21/5508

Similar Items

Similar Items